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Introduction
Evidences are accumulating that adipose tissue releases 
various active metabolic compounds, including pro-in-
flammatory cytokines (1). These compounds consist, iri-
sin, leptin, adipsin, resistin, angiotensinogen, tumor ne-
crosis factor-a (TNF-a), plasminogen activator inhibitor 
type-1 and interleukin (IL6). Therefore, patients whose 
clearance of cytokines is impaired, as in chronic kidney 
disease (CKD), may be prone to insulin resistance and ac-
celerated atherosclerosis (2).
Adiponectin is a 244 amino acid, 30 kDa protein encoded 
by the apM1 gene and related to a group of adipocyte-
specific secretory proteins known as “adipokines” (3). 
Adiponectin circulates in human plasma in three major 
oligomeric forms: a low-molecular weight (LMW) trimer, 
a middle-molecular weight (MMW) hexamer, and high-
molecular weight (HMW) 12- to 18-mers (4). Adiponec-
tin is reported to be rich in human blood, with its plasma 
levels in the mg/ml range and, thus, accounting for 0.01% 
of total plasma protein (5). Adiponectin is an adipokine 
with anti-atherogenic properties (6).
High circulating adiponectin is strongly associated with 
reduced cardiovascular risk and low adipose tissue adipo-
nectin transcriptional expression is associated with hypoa-
diponectinemia and could influence the insulin resistance 
and cardiovascular disease in obesity and type 2 diabetes 
(7). Chronic kidney disease (CKD) is a unique condition 
with exceedingly high incidence of insulin resistance and 
cardiovascular morbidity and mortality (8,9), and is para-
doxically associated with elevated plasma adiponectin. 
Plasma adiponectin level is dependent on kidney func-
tion, being markedly in creased among patients with kid-
ney impairment (10). 
Therefore, in this review article, we performed a Medline 
(PubMed) search, to identify articles published during the 
last 10 years (with special focus on papers published dur-
ing the last 3 years), changing the adiponectin levels in 
CKD patients under clinical conditions.
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Adiponectin is a multifunctional cytokine that has a role in regulating inflammation. In 
patients without chronic renal failure (CRF) and type 2 diabetics, decreased adiponectin 
levels are associated with insulin resistance. Lower serum plasma adiponectin values are link 
to larger tumor size and metastasis in clear-cell carcinoma of the kidney too. However, in 
patients with established chronic kidney disease (CKD), adiponectin levels are elevated and 
positively predict progression of disease. In addition, increased levels of serum adiponectin of 
hemodialysis patients were associated with decrease in bone mineral density in hemodialysis 
patients. Thus, depending on type of renal failure should be adjusted the adiponectin levels in 
patients. In CKD patients without diabetic, decreasing adiponectin levels by ARB drugs may 
be appropriate for inhibition of disease progression.
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Clinical implications
Ho et al (11) reported that uremic patients had one-third 
of the levels of adiponectin (P < 0.001) in compared with 
nonuremic patients, while females had a 1.5-fold higher 
levels of adiponectin.
Plasma adiponectin level was significantly higher in CKD 
patients than control group (P < 0.05) and in CKD patients 
plasma adiponectin inversely correlated with glomerular 
filtration rate (GFR) (r = -0.570, P < 0.001) (12) and cre-
atinine (r = -0.423; P < 0.01) (13). Another study showed 
that adiponectin correlated inversely with GFR (r = -0.45; 
P < 0.001), body mass index (BMI) (r = -0.33; P < 0.01), 
and visceral fat (r = -0.49; P < 0.001), while a positive asso-
ciation with amount of proteinuria was detected (r = 0.21; 
P < 0.05) (14). 
The mean adiponectin levels in the pre-dialysis groups 
were significantly lower than in the chronic ambulatory 
peritoneal dialysis (CAPD) group (P < 0.05). The levels of 
adiponectin were increased for all patients with chronic 
renal failure (CRF) (15).
For patients with normal range GFR and type 2 diabetes, 
albuminuria inversely correlated with plasma adiponec-
tin (r = −0.31, P < 0.05) (16), while plasma adiponectin 
positively correlates to intercellular leukocyte adhesion 
molecule (17). Therefore, adiponectin is associated with 
parameters of kidney function at the stage of apparently 
normal kidney function in type 2 diabetes (16).
Lenghel et al (17) concluded that median adiponectin was 
not significantly different in diabetic and non-diabetic 
subjects, however, the odds ratio comparing the highest 
tertile to the lower two tertiles was significant (1.9; 95% 
CI, 1.1, 3.6). In addition, higher adiponectin was indepen-
dently associated with lower eGFR and higher urinary al-
bumin levels (17).
Markedly elevated plasma adiponectin serum values were 
observed in CKD patients (18,19). In hemodialysis pa-
tients, the plasma levels of HMW adiponectin were sig-
nificantly higher than CKD patients (20). In hemodialysis 
patients, adiponectin is an indicator for high-density lipo-
protein cholesterol (HDL-C) and total-cholesterol levels 
and is twice its values in these patients (21).
Multivariate analysis for kidney transplant recipient pa-
tients showed that the presence of metabolic syndrome 
early after transplantation was independently associated 
with decreased plasma values of adiponectin (β: -6.39, r 
(2) 0.195, P < 0.0001) and increased risk for clinical events 
(OR: 5.6, 95% CI: 1.9, 16.5; P < 0.01) (22). Taherimah-
moudi et al (23), described that adiponectin levels were 
remarkably higher in the patient group before transplan-
tation when compared with healthy subjects (P < 0.001) 
and after transplantation this level remained significantly 
higher (P < 0.001). In post-transplant south Asian patients 
the level of total and HMW adiponectin are lower and 
may be a novel marker for cardiovascular risk factor (24).
Okuno et al (25), demonstrated that in hemodialysis pa-
tients increased levels of serum adiponectin were related 
with decreases in bone mineral density. Therefore adipo-
nectin may has participation in bone resorption especially 
in end-stage renal disease (ESRD) patients (25). Other 
changes in adiponectin level include decreased level in 
clear-cell carcinoma of the kidney depend on tumor size 
and metastasis (26), and in carotid arteriosclerosis (27). 
However, there is no significant relationship between adi-
ponectin level and all-cause mortality and cardiovascular 
death (28). Zoccali et al (29), emphasized that low plasma 
level of adiponectin and high level of norepinephrine con-
tributing to reverse cardiovascular events in nondiabetic 
hemodialysis (HD) patients. 
 In patients with CKD changes in HMW-adiponectin was 
significantly correlated with changes in eGFR (r = 0.597, 
P = 0.001) (30). In another investigation, although 60% of 
subjects with CKD have CAD, plasma levels of adiponec-
tin were not decreased in subjects with CRF compared 
with controls (17.02 ± 9.8 versus 16.40 ± 9.0; P = 0.78). 
Urinary adiponectin levels, associates inversely with GFR 
(r = −0.4; P < 0.05) and plasma adiponectin levels (r = 0.9; 
P < 0.001) (31). In hypertensive stage III-IV CKD indi-
viduals, no alterations in inflammatory markers, total or 
HMW adiponectin was detected (32). In individuals with 
CAD, metabolic syndrome is related to a lower serum 
HMW adiponectin, while the presence of CKD is asso-
ciated with increasing of the serum HMW adiponectin 
(33). In obesity, CKD at early stages develops in parallel 
with atherosclerotic process of the carotid arteries, which 
correlates with attenuation of organ-protecting properties 
of adiponectin (34). To found the effect of losartan of the 
level of adiponectin, we recently conducted a randomized 
double blind clinical trial investigation, on a group of non-
diabetic individuals, who were on routine hemodialysis 
program. In our study, exclusion criteria were presence 
of chronic active or infections, taking angiotensin con-
verting enzyme or renin–angiotensin system blockers or 
presence of diabetes. Individuals were allocated into two 
groups. First group was received losartan 12.5 mg twice 
in a day for the first week, then 25 mg twice/day during 
the second week and finally, they received 75 mg/day (50 
mg in morning, 25 mg for evening) from the third week to 
the end of 16th week. Hemodialysis subjects of the second 
group received placebo. Our patients consisted of 73 non-
diabetic hemodialysis participants (females = 33) enrolled 
to the study. The range of subjects’ age was from 13 to 91 
years. In our investigation, the mean (±SD) of serum adi-
ponectin value in all subjects was 10.6 (±3.9) µg/ml. In our 
study, a significant reduction of serum adiponectin serum 
value after 4 months of treatment by losartan (8.86±3.43 
of interventional group versus 10.71 ± 3.94 control group; 
P < 0.05) was detected. Interestingly, none of the patients 
had serum potassium value >5 mg/dl or episode of hypo-
tension during our study. In this study, we concluded that, 
the diminution in serum adiponectin value in non-diabet-
ic patients on routine hemodialysis by losartan might offer 
potential protection in these groups of patients. However, 
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Table 1. The clinical impact of adiponectin in CKD patients
Study Population Finding
Sedighi and 
Abediankenari (12)
42 CKD patients and 46 healthy 
persons
Plasma adiponectin level was significantly higher in CKD patients than control group 
(P < 0.05) and inversely correlated with GFR (r = -0.570, P < 0.001).
Kir et al (15)
37 patients with CKD on 
conservative treatment, 34 PD 
on CAPD, 35 HD and CAPD, and 
25 healthy volunteers
The mean adiponectin levels in the predialysis groups were significantly lower than in the 
CAPD group (P < 0.05). The levels of adiponectin was increased for all patients with CRF.
Stępień et al (13) 67 non-diabetic obese: patients 
without chronic CKD (n = 52)
Negative correlations occurred between creatinine and visceral adiposity index 
(r = -0.332; P < 0.05), body adiposity index (r = -0.619; P < 0.0001), and adiponectin 
(r =-0.423; P < 0.01).
Lenghel et al (17) 79 consecutive type 2 diabetic 
outpatients and 46 controls
Plasma adiponectin positively correlates to intercellular leukocyte adhesion molecule.
Barlovic et al (16) 52 patients with normal range 
GFR and type 2 diabetes
Albuminuria correlated with plasma adiponectin (r = -0.31, P < 0.05). Adiponectin is 
associated with parameters of kidney function already at the stage of apparently normal 
kidney function in type 2 diabetes.
Ho et al (11) 71 patients Compared with nonuremic patients, uremic patients had one-third of the levels of 
adiponectin (P < 0.001). Females had 1.5-fold higher levels of adiponectin.
Mills et al (36) 201 patients with CKD and 201 
controls without
Median adiponectin was not significantly different in cases and controls, but the odds 
ratio comparing the highest tertile to the lower two tertiles was significant (1.9; 95% CI, 
1.1, 3.6). In addition, higher adiponectin was independently associated with lower eGFR 
and higher urinary albumin levels.
Kamimura et al. 
(14) 98 CKD patients
Adiponectin correlated with GFR (r = -0.45; P < 0.001), proteinuria (r = 0.21; P < 0.05), BMI 
(r = -0.33; P < 0.01), and visceral fat (r = -0.49; P < 0.001).
Jorsal et al (37)
58 with normoalbuminuria, 
43 with persistent 
microalbuminuria, and 44 with 
persistent macroalbuminuria
Urinary adiponectin increased with increasing levels of urinary albumin excretion (P < 
0.01). Urinary adiponectin was associated with markers of tubular damage (P < 0.01).
Shoji et al (38)
103 patients with ESRD 
undergoing HD and 166 healthy 
subjects
Plasma adiponectin correlated negatively with plasma TG and positively with HDL-C in 
both healthy and ESRD groups.
Elshamaa et al (18)
78 advanced CKD (stages 4 and 
5) pediatric patients undergoing 
maintenance HD or CT
Markedly (P < 0.01) elevated plasma adiponectin levels were detected in CKD patients, 
especially CT patients, compared to control subjects.
Nakagawa et al 
(20)
144 HD patients and 30 patients 
with CKD
Plasma HMW adiponectin levels in hemodialysis patients were significantly higher than 
those in patients with CKD, negatively associated with visceral fat area and serum TG and 
positively associated with plasma total adiponectin.
Ribeiro et al (21) 187 HD patients and 25 healthy
Adiponectin almost doubled its values in patients and seems to be an important 
determinant in HDL-C and total cholesterol levels, improving the lipid profile in these 
patients.
Roubicek et al (19) 15 women with ESRD and 17 
healthy women
Serum concentrations of adiponectin was significantly higher in the ESRD versus control 
group.
Kaynar et al (39)
150 patients, without 
active infections or chronic 
inflammatory conditions
Adiponectin and resistin levels in predialysis, peritoneal dialysis and hemodialysis patients 
were significantly higher than control group (P < 0.001). This study had given significant 
positive correlations between presence of PEW and serum adiponectin levels (r = 0.349, 
P < 0.001). High serum resistin and adiponectin levels might have a role in development 
of PEW among dialysis patients.
Campbell et al (32) 20 hypertensive stage III-IV CKD 
patients
There was no change in inflammatory markers, total or HMW adiponectin.
Landau et al (40) 2418 individuals without 
reported diabetes at baseline
Adiponectin was associated with IR in those without CKD but not in those with CKD. In 
mainly Stage 3 CKD, kidney function is associated with IR; except for adiponectin, the 
correlates of IR are similar in those with and without CKD.
Fonseca et al (41)
40 consecutive adult patients 
with ESRD who were undergoing 
kidney transplantation
Kidney graft function is an independent determinant of leptin levels, but not of 
adiponectin.
Alam et al (42)
987 prevalent KTR on all-cause 
mortality and death-censored 
graft failure
Elevated adiponectin levels are associated with higher risk for death but not allograft 
failure in prevalent KTR.
Kulshrestha et al 
(22)
74 previously nondiabetic KTR 
patients
Multivariate analysis showed that the presence of metabolic syndrome early after 
transplantation was independently associated with depressed plasma adiponectin levels 
(β -6.39, r(2) 0.195, P < 0.0001) and increased risk for clinical events (OR: 5.6, 95% CI: 1.9, 
16.5; P < 0.01).
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Taherimahmoudi 
et al (23)
67 candidates with ESRD along 
with 30 healthy unrelated donors
Adiponectin levels were remarkably higher in the patient group before transplantation 
when compared with healthy subjects (P < 0.001) and remained significantly higher 
thereafter (P < 0.001).
Prasad et al (24) 129 clinically stable age-matched 
KTR
Total and HMW adiponectin concentrations are lower in KTR and may be promising 
exploratory biomarkers of post-transplant cardiovascular risk.
Okuno et al (25) 114 male HD patients
Increased levels of serum adiponectin were associated with decrease in bone mineral 
density in male hemodialysis patients. Adiponectin may play a role in mineral and bone 
disorder, possibly in bone resorption, of patients with CKD 5D.
Wang et al (28) 238 ESRD patients on 
maintenance PD
Plasma adiponectin showed no significant association with all-cause mortality and 
cardiovascular death.
Hayashi et al (27) 95 CKD patients without dialysis 
and 81 non-CKD patients
Higher adiponectin levels were observed in CKD patients compared with non-CKD patients. 
After adjusting for other risk factors, low levels of adiponectin were independently 
correlated with carotid arteriosclerosis in CKD patients
Toyama et al (30) Patients with CAD Changes in HMW-adiponectin was significantly correlated with changes in eGFR (r = 
0.597, P < 0.001).
Yaturu et al (31) 43 subjects with CKD compared 
with those of 34 control subjects
Although 60% of subjects with CKD have CAD, plasma levels of adiponectin were not 
decreased in subjects with CKD compared with controls (17.02 ± 9.8 vs. 16.40 ± 9.0 with 
P = 0.78). Urinary adiponectin levels correlate inversely with GFR (r = −0.4; P < 0.05) and 
plasma adiponectin levels (r = 0.9; P < 0.0001).
Hara et al (33) 228 consecutive patients with CAD
In individuals with CAD, metabolic syndrome is associated with a lower serum HMW 
adiponectin, while the presence of CKD is associated with elevation of the serum HMW 
adiponectin.
Saginova et al (34) 86 obese patients In obesity, CKD at early stages develops in parallel with atherosclerotic lesion of the carotid 
arteries, which correlates with attenuation of organ-protecting properties of adiponectin.
Zoccali et al (29) 192 nondiabetic HD patients Low adiponectin and high norepinephrine seem to be interacting factors in the dismal 
cardiovascular outcomes with ESRD.
Pinthus et al (26)
42 patients with clear-cell RCC, 
including 15 with metastatic 
disease
Lower plasma adiponectin levels are associated with larger tumor size and metastasis in 
clear-cell carcinoma of the kidney.
Mardani et al (35) 73 non-diabetic HD patients
A significant decrease of serum adiponectin level after four months of treatment by 
losartan (8.86 ± 3.43 of interventional group versus 10.71 ± 3.94 control group; P < 0.05) 
was observed..
Abbreviations: CKD, chronic kidney disease;  HD, hemodialysis; PD, peritoneal dialysis; GFR, glomerular filtration rate; CAD, chronic kidney disease; 
CAPD, continuous ambulatory peritoneal dialysis; ESRD, end-stage renal disease; HMW, high-molecular weight; HDL-C, high-density lipoprotein 
cholesterol; TG, triglycerides; KTR, kidney transplant recipients; PEW, protein-energy wasting; BMI, body mass index; CT, conservative treatment; IR, 
insulin resistance; OR, odds ratio; RCC, renal cell carcinoma.
the mechanism liable for this reduction remains to be in-
vestigated (35).
Conclusion
Adiponectin is a multifunctional cytokine which has a 
role in regulating inflammation. In patients without CKD 
such as type 2 diabetics, decreased adiponectin levels are 
associated with insulin resistance. Lower plasma adipo-
nectin levels are associated with larger tumor size and 
metastasis in clear-cell carcinoma of the kidney. However, 
in patients with established CKD, adiponectin levels are 
elevated and positively predict progression of disease. In 
addition, increased levels of serum adiponectin of hemo-
dialysis patients were associated with decrease in bone 
mineral density in hemodialysis patients. Thus, depend-
ing on type of renal failure should be adjusted the adipo-
nectin levels in patients. In CKD patients without diabetic, 
decreasing adiponectin levels by angiotensin II receptor 
blockers (ARBs) may be appropriate for inhibition of dis-
ease progression.
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